180 related articles for article (PubMed ID: 35356000)
21. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction.
Geusens PP; Landewé RB; Garnero P; Chen D; Dunstan CR; Lems WF; Stinissen P; van der Heijde DM; van der Linden S; Boers M
Arthritis Rheum; 2006 Jun; 54(6):1772-7. PubMed ID: 16736519
[TBL] [Abstract][Full Text] [Related]
22. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.
Pettit AR; Walsh NC; Manning C; Goldring SR; Gravallese EM
Rheumatology (Oxford); 2006 Sep; 45(9):1068-76. PubMed ID: 16490750
[TBL] [Abstract][Full Text] [Related]
23. Prolactin blocks the expression of receptor activator of nuclear factor κB ligand and reduces osteoclastogenesis and bone loss in murine inflammatory arthritis.
Ledesma-Colunga MG; Adán N; Ortiz G; Solís-Gutiérrez M; López-Barrera F; Martínez de la Escalera G; Clapp C
Arthritis Res Ther; 2017 May; 19(1):93. PubMed ID: 28506283
[TBL] [Abstract][Full Text] [Related]
24. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
Tai YT; Cho SF; Anderson KC
Front Immunol; 2018; 9():1822. PubMed ID: 30147691
[TBL] [Abstract][Full Text] [Related]
25. Dysregulated PD-L2 is correlated with disease activity and inflammation in rheumatoid arthritis.
Xiong J; Yang J; Sun Y; Chen Y; Guo Y; Liu C; Sun J
Immunogenetics; 2023 Oct; 75(5):425-431. PubMed ID: 37405419
[TBL] [Abstract][Full Text] [Related]
26. Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis.
Lubberts E; Oppers-Walgreen B; Pettit AR; Van Den Bersselaar L; Joosten LA; Goldring SR; Gravallese EM; Van Den Berg WB
Arthritis Rheum; 2002 Nov; 46(11):3055-64. PubMed ID: 12428250
[TBL] [Abstract][Full Text] [Related]
27. Fengshi Qutong capsule ameliorates bone destruction of experimental rheumatoid arthritis by inhibiting osteoclastogenesis.
Li Y; Yang C; Jia K; Wang J; Wang J; Ming R; Xu T; Su X; Jing Y; Miao Y; Liu C; Lin N
J Ethnopharmacol; 2022 Jan; 282():114602. PubMed ID: 34492323
[TBL] [Abstract][Full Text] [Related]
28. Unbalanced expression of membrane-bound and soluble inducible costimulator and programmed cell death 1 in patients with myasthenia gravis.
Yan X; Gu Y; Wang C; Sun S; Wang X; Tian J; Wang M; Ji X; Duan X; Gao H; Fang Q; Dong W; Zhang X; Xue Q
Clin Immunol; 2019 Oct; 207():68-78. PubMed ID: 31374257
[TBL] [Abstract][Full Text] [Related]
29. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha.
Dai SM; Nishioka K; Yudoh K
Ann Rheum Dis; 2004 Nov; 63(11):1379-86. PubMed ID: 15479886
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis.
Kwok SK; Cho ML; Park MK; Oh HJ; Park JS; Her YM; Lee SY; Youn J; Ju JH; Park KS; Kim SI; Kim HY; Park SH
Arthritis Rheum; 2012 Mar; 64(3):740-51. PubMed ID: 21968544
[TBL] [Abstract][Full Text] [Related]
31. Deletion of CD74, a putative MIF receptor, in mice enhances osteoclastogenesis and decreases bone mass.
Mun SH; Won HY; Hernandez P; Aguila HL; Lee SK
J Bone Miner Res; 2013 Apr; 28(4):948-59. PubMed ID: 23044992
[TBL] [Abstract][Full Text] [Related]
32. Soluble programmed death molecule 1 (sPD-1) as a predictor of interstitial lung disease in rheumatoid arthritis.
Xu L; Jiang L; Nie L; Zhang S; Liu L; Du Y; Xue J
BMC Immunol; 2021 Oct; 22(1):69. PubMed ID: 34654367
[TBL] [Abstract][Full Text] [Related]
33. Rheumatoid and pyrophosphate arthritis synovial fibroblasts induce osteoclastogenesis independently of RANKL, TNF and IL-6.
Dickerson TJ; Suzuki E; Stanecki C; Shin HS; Qui H; Adamopoulos IE
J Autoimmun; 2012 Dec; 39(4):369-76. PubMed ID: 22867712
[TBL] [Abstract][Full Text] [Related]
34. Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours.
Mair MJ; Pajenda S; Ilhan-Mutlu A; Steindl A; Kiesel B; Widhalm G; Dieckmann K; Feldmann K; Hainfellner J; Marosi C; Müllauer L; Wagner L; Preusser M; Berghoff AS
ESMO Open; 2020 Nov; 5(6):e000863. PubMed ID: 33184096
[TBL] [Abstract][Full Text] [Related]
35. Unbalanced expression of membrane-bound and soluble programmed cell death 1 and programmed cell death ligand 1 in systemic juvenile idiopathic arthritis.
Cai L; Zhang C; Wu J; Zhou W; Chen T
Clin Immunol; 2021 Aug; 229():108800. PubMed ID: 34289424
[TBL] [Abstract][Full Text] [Related]
36. TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis.
Dharmapatni AA; Smith MD; Crotti TN; Holding CA; Vincent C; Weedon HM; Zannettino AC; Zheng TS; Findlay DM; Atkins GJ; Haynes DR
Arthritis Res Ther; 2011 Mar; 13(2):R51. PubMed ID: 21435232
[TBL] [Abstract][Full Text] [Related]
37. Immune Function and Mechanism of Costimulating Molecules PD-1 and OX40 in Rheumatoid Arthritis.
Huang Y; Pan C; Liu Y; Lin S; Zhan Y; Zhang Y; Zhan F
J Interferon Cytokine Res; 2020 Nov; 40(11):530-539. PubMed ID: 33201766
[TBL] [Abstract][Full Text] [Related]
38. Comparative analysis of the levels of soluble forms of receptor and ligand of the immunity control point PD-1/PD-L1 in the blood serum of patients with typical bone osteosarcoma and chondrosarcoma.
Kushlinskii NE; Alferov AA; Boulytcheva IV; Timofeev YS; Korotkova EA; Khvan OT; Kuzmin YB; Kuznetsov IN; Bondarev AV; Shchupak MY; Sokolov NY; Efimova MM; Gershtein ES; Sushentsov EA; Aliev MD; Musaev ER
Klin Lab Diagn; 2020 Dec; 65(11):669-675. PubMed ID: 33301655
[TBL] [Abstract][Full Text] [Related]
39. RANKL expression in chondrocytes and its promotion by lymphotoxin-α in the course of cartilage destruction during rheumatoid arthritis.
Takeshita A; Nishida K; Yoshida A; Nasu Y; Nakahara R; Kaneda D; Ohashi H; Ozaki T
PLoS One; 2021; 16(7):e0254268. PubMed ID: 34234380
[TBL] [Abstract][Full Text] [Related]
40. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.
Takayanagi H; Iizuka H; Juji T; Nakagawa T; Yamamoto A; Miyazaki T; Koshihara Y; Oda H; Nakamura K; Tanaka S
Arthritis Rheum; 2000 Feb; 43(2):259-69. PubMed ID: 10693864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
